DARIA: daratumumab with ixazomib and dexamethasone for R/R myeloma

(2:38)

Daratumumab with Ixazomib and Dex in Pts with One Prior Lenalidomide-Based Regimen: The DARIA Study

(5:28)

DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients

(2:18)

Clinical Trial: Darzalex (daratumamab) with Revlimid/Velcade/Dex for Newly Diagnosed Myeloma

(7:31)

Re-treatment of patients refractory to daratumumab

(3:57)

All About Darzalex (daratumumab) #myeloma

(14:28)

Daratumumab: no evidence of disease after treatment?

(1:5)

Does using daratumumab make response-monitoring difficult?

(3:24)

Daratumumab Revolutionizing How Myeloma Is Treated

(5:53)

Daratumumab Plus VRd for Multiple Myeloma | NEJM

(2:24)

Carfilzomib 2x Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and Dex

(6:44)

Daratumumab in Multiple Myeloma

(11:24)

IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma

(4:23)

Dr. Shah on Daratumumab-Based Regimens in Frontline Multiple Myeloma

(1:57)

The future of daratumumab in multiple myeloma

(52)

Dr. Bahlis on Daratumumab Plus Lenalidomide and Dexamethasone in Multiple Myeloma

(1:17)

Case study: daratumumab in a relapsed patient

(3:27)

Daratumumab + Pomalidomide \u0026 Dexamethasone Effective in Relapsed/Refractory Multiple Myeloma

(5:3)

Daratumumab in the treatment of multiple myeloma

(2:13)

Daratumumab in multiple myeloma: an overview of 3 key trials

(3:51)